Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes

  • Wi Sun Ryu
  • , Dawid Schellingerhout
  • , Keun Sik Hong
  • , Sang Wuk Jeong
  • , Beom Joon Kim
  • , Joon Tae Kim
  • , Kyung Bok Lee
  • , Tai Hwan Park
  • , Sang Soon Park
  • , Jong Moo Park
  • , Kyusik Kang
  • , Yong Jin Cho
  • , Hong Kyun Park
  • , Byung Chul Lee
  • , Kyung Ho Yu
  • , Mi Sun Oh
  • , Soo Joo Lee
  • , Jae Guk Kim
  • , Jae Kwan Cha
  • , Dae Hyun Kim
  • Jun Lee, Moon Ku Han, Man Seok Park, Kang Ho Choi, Matthias Nahrendorf, Juneyoung Lee, Hee Joon Bae, Dong Eog Kim

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Objective: We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke. Methods: This multicenter magnetic resonance imaging (MRI)-based study included 5,700 consecutive patients with acute first-ever ischemic stroke, who did not undergo intravenous thrombolysis or endovascular thrombectomy, from May 2011 through February 2014. Propensity score-based augmented inverse probability weighting was performed to estimate adjusted effects of pre-stroke aspirin use. Results: The mean age was 67 years (41% women), and 15.9% (n = 907) were taking aspirin before stroke. Pre-stroke aspirin use (vs nonuse) was significantly related to a reduced infarct volume (by 30%), particularly in large artery atherosclerosis stroke (by 45%). In cardioembolic stroke, pre-stroke aspirin use was associated with a ~50% lower incidence of END (adjusted difference = −5.4%, 95% confidence interval [CI] = −8.9 to −1.9). Thus, pre-stroke aspirin use was associated with ~30% higher likelihood of favorable outcome (3-month modified Rankin Scale score < 3), particularly in large artery atherosclerosis stroke and cardioembolic stroke (adjusted difference = 7.2%, 95% CI = 1.8 to 12.5 and adjusted difference = 6.4%, 95% CI = 1.7 to 11.1, respectively). Pre-stroke aspirin use (vs nonuse) was associated with 85% less frequent cerebral thrombus-related susceptibility vessel sign (SVS) in large artery atherosclerosis stroke (adjusted difference = −1.4%, 95% CI = −2.1 to −0.8, p < 0.001) and was associated with ~40% lower SVS volumes, particularly in cardioembolic stroke (adjusted difference = −0.16 cm3, 95% CI = −0.29 to −0.02, p = 0.03). Moreover, pre-stroke aspirin use was not significantly associated with hemorrhagic transformation (adjusted difference = −1.1%, p = 0.09). Interpretation: Pre-stroke aspirin use associates with improved functional independence in patients with first-ever ischemic large arterial stroke by reducing infarct volume and/or END, likely by decreasing thrombus burden, without increased risk of hemorrhagic transformation. ANN NEUROL 2021;90:763–776.

Original languageEnglish
Pages (from-to)763-776
Number of pages14
JournalAnnals of Neurology
Volume90
Issue number5
DOIs
StatePublished - Nov 2021

Fingerprint

Dive into the research topics of 'Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes'. Together they form a unique fingerprint.

Cite this